• 한국임상약학회지
• /
• 제10권1호
• /
• pp.25-29
• /
• 2000

Bioequivalence of cisapride-containing $Cisaplus^{(R)}$ tablets (Daewoong Co.) to reference $Prepulsid^{(R)}$ tablets (Janssen Co.) was evaluated according to the guidelines of Korea Food and Drug Administration (KFDA). Sixteen healthy volunteers were divided randomly into two groups and administered orally at a cisapride dose of 10 mg in a $2\times2$ crossover design. There was a 1-week washout period between the treatments. Blood samples were taken at predetermined time intervals for 48 hr and the plasma cisapride concentrations were determined by an HPLC with UV detector. The area under the plasma drug concentration-time curve (AUC) was caltulated from time zero to the last sampling time by a linear trapezoidal method. The maximum observed plasma drug concentration ($C_{max}$) and the time to $C_{max}\;(T_{max})$ were estimated directly from the drug concentration-time data. Analysis of variance (ANOVA) showed that the apparent differences for AUC, $C_{max}\;and\;T_{max}$ were $-7.52\%,\;-8.91\%\;and\;-15.55\%$, respectively. The minimum detectable differences for AUC, $C_{max}\;and\;T_{max}$ between formulations were $14.52\%,\;11.57\%\;and\;28.00\%$ respectively, at $\alpha=0.05\;and\;1-\beta=0.8\;levels.\;The\;90\%$ confidence intervals for AUC, $C_{max}\;and\;T_{max}\;were\;-16.00\sim0.97\%,\;-15.67\sim-2.15\%\;and\;-31.88\%\sim0.84\%$, respectively. These results satisfy the bioequivalence criteria of KFDA guidelines, indicating that the two formulations of cisapride are bioequivalent.

• 자원리싸이클링
• /
• 제33권1호
• /
• pp.22-30
• /
• 2024

2차원 물질 MXene의 전구체로 사용되는 Ti₃AlC₂ MAX 상 합성을 위해, 출발물질로써 타이타늄 (Ti) 스크랩을 활용하는 것은 경제적인 접근이 될 수 있다. 본 연구는 Ti 스크랩을 활용하여 Ti₃AlC₂ MAX상의 상분율 향상을 위한 합성 조건의 최적화를 수행하였다. Ti 스크랩으로부터 수소화-탈수소화(hydrogenation-dehydrogenation, HDH) 공정에 의해 제조된 Ti 분말의 산소 함량은 고상탈산(Deoxidation in solid state, DOSS) 공정을 통하여 효과적으로 감소되었다. 최적 합성 조건은 25 ~ 32 ㎛의 DOSS-Ti, Al, graphite 분말을 3:1.1:2의 몰 비율로 혼합하여 합성되었다. 이 때의 Ti₃AlC₂, TiC 및 Al₃Ti의 상분율은 각각 97.25%, 0.93%, 1.82%로 나타났으며, 25 ~ 45 ㎛의 Ti₃AlC₂ MAX 분말의 산소 함량은 4,210 ppm으로 확인되었다.

• 수산해양교육연구
• /
• 제26권2호
• /
• pp.316-321
• /
• 2014

The pharmacokinetics of erythromycin (EM) after oral administration was studied in the cultured olive flounder, Paralichthys olivaceus, using LC/MS/MS. After single- or multiple-dose administration of EM (50, 100, 200 mg/kg body weight and 50 mg/kg for 5 days) by oral route in olive flounder ($350{\pm}40g$, $22{\pm}0.5^{\circ}C$), the concentration in the serum was determined at 1, 3, 6, 9, 24, 72, 120, 168, 264, 360, 504 and 720 h post-dose. The kinetic profile of absorption, distribution and elimination of EM in serum were analyzed fitting to a two-compartment model by WinNonlin program. The area under the concentration-time curve (AUC), maximum concentration ($C_{max}$), time for maximum concentration ($T_{max}$) following oral administration of 50, 100 and 200 mg/kg b.w. and 50 mg for 5 days. EM was $165.3hr^*{\mu}g/m{\ell}$ ($C_{max}$, $34.63{\mu}g/m{\ell}$; $T_{max}$, 1.56 hr), $212.8hr^*{\mu}g/m{\ell}$ ($C_{max}$, $60.38{\mu}g/m{\ell}$; $T_{max}$, 3.99 hr), and $592.37hr^*{\mu}g/m{\ell}$ ($C_{max}$, $63.01{\mu}g/m{\ell}$; $T_{max}$, 4 hr), respectively. The results of this study related to dosage and ${\mu}{\cdot}$withdrawal times could be used for prescription of EM in field for the treatment of bacterial diseases in olive flounder.

• 한국양식학회지
• /
• 제15권4호
• /
• pp.253-260
• /
• 2002

To find the optimal rearing conditions for Saxidomus purpuratus juvenile, filtering activity was estimated as functions of algal concentration and temperature by measuring the rates of clearance (CR) and ingestion (IR), when S. purpuratus was feeding. The clams were fed on unialgal diet of Isochrysis galbana at 6 algal concentrations (4.6$\times$$10^4$~2.6$\times$$10^6$ cells/ml) and at 6 temperatures (5, 10, 15, 20, 25, and 30^{\circ}C ). Algal concentration significantly affected the CR and the IR at all temperatures. At lower algal concentrations, CR increased, but decreased beyond a particular concentration. The maximum CR ($CR_{max}$) at 5, 10, 15, 20, 25, and 30^{\circ}C were 0.30, 1.73, 5.95, 15.17, 21.12, and 0.33 $l/g/h$, respectively. Below the level of 5.6$\times$10$^{5}$ cells/ml, IR increased as algal concentration increased, but was saturated at higher concentrations. To maintain high growth rate of S. purpuratus, I. galbana should be supplied with more than 5.6$\times$10$^{5}$ cells/ml. The maximum IR ($IR_{max}$) at 5, 10, 15, 20, 25 and30^{\circ}C were $2.2$\times$10^8, $1.5\times$10^9, 3.4$\times$10^9, 4.9$\times$10^9, 5.3$\times$10^9, and 1.0$\times$10^8$ cells/g/h, respectively. As for temperature, both $CR_max$ and $IR_max$ increased remarkably with raising temperature from 5 to 25^{\circ}C, but rapidly decreased at 30^{\circ}C. Between 15 and 25^{\circ}C $CR_{max} and IR_{max}$ were higher and most stable, At this temperature range, the $Q_{10}/s for CR_{max} and IR_{max}$ were 3.5 and 1.6, respectively. Therefore the optimal thermal range for the juvenile is 15~$25^{\circ}C$. The annual variation in IR$_{max}$ predicted by natural seawater temperature shows that inactive period (with lower $IR_max$) lasts for 5 months (from December to April). To ensure higher growth of juvenile during this inactive period at hatcheries, rearing temperature should be elevated to $15^{\circ}C$.>.

• 한국태양에너지학회:학술대회논문집
• /
• 한국태양에너지학회 2009년도 추계학술발표대회 논문집
• /
• pp.26-31
• /
• 2009

This study was analysed influence of urban higher temperature in Busan about time series analysis of AWS data. The results are as follows. (1) The temperature of Busan show min $13.2^{\circ}C$ ~max $15.8^{\circ}C$ by 50 years, it is on the rise. (2) The seasonal adjustment series, summer appeared min $17.5^{\circ}C$ ~max $28.9^{\circ}C$ with primitive series similarly. The winter was min $-11.4^{\circ}C$ ~max $17.9^{\circ}C$, the minimum temperature was more lowly than primitive series and maximum temperature was more higher than primitive series. The results, seasonal adjustment series is guessed with influence difference urban structural element beside seasonal factor. (3) Regional analytical result, January appeared with range of min 28% ~max 196% of the seasonal factor and August appeared min 90% ~ max 106%. One of the case which is of 100% or more of the seasonal factor January 12nd~17th, August appears at the 15~17th.

• 약학회지
• /
• 제45권2호
• /
• pp.220-226
• /
• 2001

A bioequivalence study of Lovastati $n^{TM}$ tablets (Dong Sung Pharmaceutical Co., Korea) to Mevaco $r^{TM}$ tablets (Choong Wae Pharmaceutical Co., Korea) was conducted according to the guidelines (No. 98-56) of Korea Food and Drug Administration (KFDA). Each tablet contained 20 mg of lovastatin. Eighteen healthy Korean male subjects received each formulation at a lovastatin dose of 80 mg (i.e., four tablets) in a 2 $\times$ 2 crossover study. There was a washout period of a week between the dose of the two formulations. Plasma concentrations of lovastatin acid were monitored by a GC/MS method for over a period of 12hr after each administration. The area under the plasma concentration-time curve from time zero to 12hr (AUC) was calculated by a linear trapezoidal method. The maximum plasma drug concentration ( $C_{max}$) and the time to reach $C_{max}$ ( $T_{max}$) were compiled from the plasma drug concentration-time data. Analysis of variance (ANOVA) of these parameters revealed that there are no differences in AUC and $C_{max}$ between the formulations. The apparent differences between the formulations in these parameters were 4.87 and 8.03% for AUC and $C_{max}$, respectively. Minimum detectable differences (%) at $\alpha$=0.1 and 1-$\beta$=0.8 were 17.84 and 15.36% for AUC and $C_{max}$ respectively. The 90% confidence intervals were -15.30~5.56 and -17.02-0.95% for AUC and $C_{max}$, respective1y. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating Mevaco $r^{TM}$ tablets and Dong Sung Lovastati $n^{TM}$ tablets are bioequivalent.ivalent.ent.alent.ent.

• Journal of Astronomy and Space Sciences
• /
• 제9권1호
• /
• pp.11-29
• /
• 1992

In 1963, Toomre built up classes of mass models for the highly flattened galaxies which have free parameters n, $a_n$ and $C_n$. In order to keep the universal dimension, we adopt parameters $b_n({C_n}^2={a_n}^{2n}+^2{b_n}^2/(n-1)!)$ insteal of $C_n$. Series of the normalized Toomre's mass models (G = $V_{max}$ =$R_{max}$ = 1, n = 1 to 7) are derived and the normalized parameters $a_n$ and $b_n$ are determined by the iteration method. Replacing parameters $a_n$ and $b_n$ to ${a_n}^l(=a_nr_{max})$ and ${b_n}^l(=b_n\cdotV_{max}/r_{max})$, we can get the generalization of Toomre's mass model.

• Journal of Pharmaceutical Investigation
• /
• 제28권3호
• /
• pp.185-191
• /
• 1998

A bioequivalence study of the Loxipen tablets (Dae Wha Pharmaceutical Co., Korea) to the Loxonin tablets (Dong Hwa Pharmaceutical Co., Korea), formulations of sodium loxoprofen anhydrous 60 mg, was conducted. Sixteen healthy Korean male subjects received each formulation at the dose of 60 mg as sodium loxoprofen anhydrous in a $2{\times}2$ crossover study. There was a 2-week washout period between the dose. Plasma concentrations of loxoprofen were monitored by an HPLC method for over a period of 6 h after each administration. AUC (area under the plasma concentration-time curve from time zero to infinity) was calculated by the linear trapezoidal and extrapolation method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ $(time\;to\;reach\;C_{max})$ were compiled from the plasma drug concentration-time data. Analysis of variance (ANOVA) revealed that there are no differences in AUC, $C_{max}$ and $T_{max}$ between the formulations. The apparent differences between the formulations in these parameters were all far less than 20% (i.e., 5.88, 7.81 and 6.09% for AUC, $C_{max}$ and $T_{max}$, respectively). Minimum detectable differences (%) at ${\alpha}=0.1$ and $1-{\beta}=0.8$ were all less than 20% difference in these parameters between the formulations were all over 0.8 (i.e., 15.81, 13.13 and 19.85 for AUC, $C_{max}$ and $T_{max}$, respectively). The 90% confidence intervals for these parameters were also within ${\pm}20%$ (i.e., $-16.52{\sim}4.77$, $-16.65{\sim}1,02$ and $-19.45{\sim}7.28%$ for AUC, $C_{max}$ and $T_{max}$, respectively). These results satisfy the bioequivalence criteria of the Korea Food and Drug Administration (KFDA) guidelines (No. 98-51). Therefore, these results indicate that the 2 formulations of loxoprofen are bioequivalent and, thus, may be prescribed interchangeably.

• Composites Research
• /
• 제22권3호
• /
• pp.74-81
• /
• 2009

본 연구는 SiC 입자 강화된 알루미늄기 복합재료와 SiC 휘스커 강화된 알루미늄기 복합재료를 이용해서 평면굽힘피로시험을 행했다. 표면미소피로균열의 발생 및 진전거동은 레프리카법으로 연속관찰을 했고 파괴원인과 파괴기구를 규명하기 위해서 주사전자현미경을 이용했다. 두 재료 모두 da/dn - $K_{max}$ 관계에서 고응력 레벨에서는 $K_{max}$의 증가에 따라 da/dn이 증가 했지만, 저응력 레벨에서는 da/dn이 감소하다가 증가하는 것을 알 수 있다.

• Journal of Pharmaceutical Investigation
• /
• 제29권1호
• /
• pp.61-66
• /
• 1999

Bioequivalence of two terazosin tablets, the $Hytrine^{TM}$ (Il-Yang Pharmaceutical Co., Ltd.) and the $Hytrine^{TM}$ (Daewon Pharmaceutical Co., Ltd.), was evaluated according to the guideline of KFDA. Sixteen normal male volunteers $(21{\sim}30\;years\;old)$ were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After one tablet containing 2 mg of terazosin was orally administered, blood was taken at predetermined time intervals and the concentration of terazosin in serum was determined with a HPLC method using spectrofluorometric detector. The pharmacokinetic parameters $(AUC_t,\;C_{max}\;and\;T_{max})$ were calculated and ANOVA was utilized for the statistical analysis of the parameters. The results showed that the differences in $AUC_t$ $C_{max}$ and $T_{max}$ between two tablets were 6.02%,3.44% and -3.67%, respectively. The powers $(1-{\beta})$ for $AUC_t$, $C_{max}$ and $T_{max}$ were 98.05%, 98.34% and 29.81 %, respectively. Detectable differences $({\Delta})$ and confidence intervals were all less than ${\pm}20%$ except $T_{max}$. $AUC_t$ and $C_{max}$ met the criteria of KFDA for bioequivalence, indicating that $Terasin^{TM}$ tablet is bioequivalent to $Hytrine^{TM}$ tablet.